Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-08-23
2011-08-23
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S318000, C544S124000, C544S129000, C546S187000, C546S194000
Reexamination Certificate
active
08003642
ABSTRACT:
The compound represented by formula (I), a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof specifically binds CCR5, so it is useful for preventing and/or treating CCR5-related diseases, for example, various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, etc.), immunological diseases (autoimmune diseases, rejection in organ transplantation, immunosuppression, psoriasis, multiple sclerosis, etc.), infectious diseases (infection with human immunodeficiency virus, acquired immunodeficiency syndrome, etc.), allergic diseases (atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, etc.), ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacterial infection diabetes cancer metastasis and so onWherein all symbols in formula are as defined in the specification.
REFERENCES:
patent: 3375256 (1968-03-01), Bach et al.
patent: 5169855 (1992-12-01), Cain
patent: 5486534 (1996-01-01), Lee et al.
patent: 6096780 (2000-08-01), Shiraishi
patent: 6268354 (2001-07-01), Nishimura
patent: 6376536 (2002-04-01), Shiraishi
patent: 6515027 (2003-02-01), Bondinell
patent: 6720321 (2004-04-01), Cirillo et al.
patent: 6765009 (2004-07-01), Francesco et al.
patent: 6894063 (2005-05-01), Greenlee et al.
patent: 6903085 (2005-06-01), Thom et al.
patent: 7053090 (2006-05-01), Habashita et al.
patent: 7071213 (2006-07-01), Friary et al.
patent: 7247725 (2007-07-01), Butora et al.
patent: 2002/0165223 (2002-11-01), Greenlee et al.
patent: 2003/0069276 (2003-04-01), Edlin et al.
patent: 2003/0083333 (2003-05-01), Cirillo et al.
patent: 2003/0100608 (2003-05-01), Cirillo et al.
patent: 2003/0114517 (2003-06-01), Greenlee et al.
patent: 2003/0195192 (2003-10-01), Haviv et al.
patent: 2004/0006081 (2004-01-01), Burrows et al.
patent: 2004/0010013 (2004-01-01), Friary et al.
patent: 2004/0082584 (2004-04-01), Habashita et al.
patent: 2004/0158067 (2004-08-01), Hutchison et al.
patent: 2005/0038100 (2005-02-01), Greenlee et al.
patent: 2005/0215557 (2005-09-01), Habashita et al.
patent: 2005/0250792 (2005-11-01), Thom et al.
patent: 2005/0261325 (2005-11-01), Butora et al.
patent: 2005/0267114 (2005-12-01), Takaoka et al.
patent: 2005/0282861 (2005-12-01), Friary et al.
patent: 2006/0178397 (2006-08-01), MacDonald et al.
patent: 2006/0178399 (2006-08-01), Nishizawa et al.
patent: 2007/0066624 (2007-03-01), Zhou et al.
patent: 2007/0167459 (2007-07-01), Habashita et al.
patent: 2007/0254886 (2007-11-01), Habashita et al.
patent: 2008/0057074 (2008-03-01), Takaoka et al.
patent: 0 449 187 (1991-10-01), None
patent: 0 748 805 (1996-12-01), None
patent: 1 020 445 (2000-07-01), None
patent: 1 236 726 (2002-09-01), None
patent: 1378510 (2004-01-01), None
patent: 1422219 (2004-05-01), None
patent: 1541574 (2005-06-01), None
patent: 1 604 981 (2005-12-01), None
patent: 1790637 (2007-05-01), None
patent: 04-356462 (1992-12-01), None
patent: 2000-128782 (2000-05-01), None
patent: 2001-518505 (2001-10-01), None
patent: 2004-528318 (2004-09-01), None
patent: 2004-534787 (2004-11-01), None
patent: 2007-063268 (2007-03-01), None
patent: 2199535 (2003-02-01), None
patent: 96/10012 (1996-04-01), None
patent: 97/36903 (1997-10-01), None
patent: 99/01127 (1999-01-01), None
patent: 99/17773 (1999-04-01), None
patent: 99/31062 (1999-06-01), None
patent: 99/32100 (1999-07-01), None
patent: 02/24636 (2002-03-01), None
patent: 02/053560 (2002-07-01), None
patent: 02/074758 (2002-09-01), None
patent: 02/074770 (2002-09-01), None
patent: 02/079186 (2002-10-01), None
patent: 02/083628 (2002-10-01), None
patent: 02/098869 (2002-12-01), None
patent: 03/020703 (2003-03-01), None
patent: 03037271 (2003-05-01), None
patent: 03/066592 (2003-08-01), None
patent: 03/104230 (2003-12-01), None
patent: 2004/026873 (2004-04-01), None
patent: 2004/043925 (2004-05-01), None
patent: 2004/046110 (2004-06-01), None
patent: 2004/080966 (2004-09-01), None
patent: 2004/096131 (2004-11-01), None
patent: 2006/030925 (2006-03-01), None
patent: 2007/022371 (2007-02-01), None
patent: 2007/105637 (2007-09-01), None
Khanapure et al. , “Synthesis and Structure—Activity Relationship of Novel, Highly Potent Metharyl and Methcycloalkyl Cyclooxygenase-2 (COX-2) Selective Inhibitors”, Journal of Medicinal Chemistry, pp. 5484-5504, vol. 46, No. 25, American Chemical Society (2003).
Ledniger et al., “Mammalian Antifertility Agents. IV. Basic 3,4-Dihydronaphthalenes and 1,2,3,4-Tetrahydro-1-Naphthols”, pp. 79-84, vol. 10, Jounal Medicinal Chemistry (1967).
International Search Report dated Jun. 1, 2004 in PCT/JP2004/003333.
Chinese Office Action dated May 11, 2007 in Application No. 2004800130029.
Russian Office Action dated Aug. 30, 2007 in Application No. 2005131833.
Statement of Third Party Observations dated May 13, 2008 in European Application No. 05785808.6.
Millet, “Potent and Selective Farnesy/Transferase Inhibitors”, J.Med. Chem., vol. 47, pp. 6812-6820 (2004).
Supplementary European Search Report dated Nov. 26, 2008.
Mashkovskiy, M.D., “Medicinal Drugs”, p. 11, vol. 1, 14th Ed., S.B. Divov, Moscow (2001).
Russian Office Action dated Jul. 9, 2009 in Application No. 2007113814.
U.S. Office Action dated Jun. 20, 2008 in U.S. Appl. No. 10/549,120.
U.S. Office Action dated Nov. 26, 2008 in U.S. Appl. No. 10/549,120.
U.S. Office Action dated Feb. 13, 2009 in U.S. Appl. No. 10/549,120.
U.S. Office Action dated Oct. 9, 2009 in U.S. Appl. No. 10/549,120.
European Office Action dated Dec. 15, 2009 issued in Application No. 04720257.7.
Singaporean Office Action dated Jan. 19, 2010 in Singapore Application No. 200806533-6.
Extended European Search Report dated Feb. 18, 2010 in European Application No. 05785808.6-1521.
Chinese Office Action dated Mar. 10, 2010 in Chinese application No. 200810133648.0.
Office Action issued on Apr. 14, 2010 in the counterpart Russian Application No. 2007113814 of co-pending U.S. Appl. No. 10/549,120.
New Zealand Office Action issued Apr. 8, 2010 in corresponding New Zealand application No. 571019.
Vietnamese Office Action issued Jun. 10, 2010 in Vietnamese application No. 1-2005-01233.
Office Action issued May 11, 2010 in the counterpart Chinese Application No. 200810133649.5 of co-pending U.S. Appl. No. 10/549,120.
Japanese Office Action issued May 18, 2010 in Japanese Application No. 2005-503613.
Shomir Ghosh et. al.: “Design, Synthesis, and Progress toward Optimization of Potent Small Molecule Antagonists of CC Chemokine Receptor 8 (CCR8)”, Journal of Medicinal Chemistry, vol. 49. No. 9, May 4, 2006; pp. 2669-2672.
Office Action issued on Sep. 10, 2010 in counterpart European application No. 04 720 257.7 of co-pending U.S. Appl. No. 10/549,120.
Office Action issued on Sep. 23, 2010 in counterpart Norwegian application No. 2005 4244 of co-pending U.S. Appl. No. 10/549,120.
Office Action issued on Sep. 28, 2010 in counterpart European application No. 05 785 808.6 of co-pending U.S. Appl. No. 11/662,639.
European Search Report issued on Oct. 19, 2010 in corresponding European application No. 07 738 169.7.
The Second Office Action dated Oct. 12, 2010 from The Patent Office of the People's Republic of China issued Chinese application No. 200580038925.4 which is a counterpart application to co-pending U.S. Appl. No. 11/662,639.
Office Action dated Oct. 19, 2010 from the Canadian Intellectual Property Office issued Canadian Application No. 2,517,888, which is a counterpart to co-pending U.S. Appl. No. 10/549,120.
Australian Office Action issued in Application No. 2005-283326; dated Nov. 9, 2010.
Hashimura Kazuya
Kusuda Shinya
Nishiyama Toshihiko
Shibayama Shiro
Ueda Junya
Anderson Rebecca
Ono Pharmaceutical Co. Ltd.
Shterengarts Samantha
Sughrue & Mion, PLLC
LandOfFree
Nitrogenated heterocyclic derivative, and pharmaceutical... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nitrogenated heterocyclic derivative, and pharmaceutical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitrogenated heterocyclic derivative, and pharmaceutical... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2701954